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Introduction
Periodontal regeneration is challenging and yet interesting 
arena of treatment strategy for the periodontitis  [1]. 
Multiple cells and cell signaling cascades involved in 
the treatment of periodontal regeneration makes it still 
as a better treatment modality, where results and clinical 
outcomes are difficult to predict. However, challenge 
of periodontal regeneration is being addressed part by 
part and results are promising with available array of 
multiple treatment modalities [2, 3].
One of the well dealt regeneration strategies commonly 
utilized in the field of periodontics is the use of platelet 
concentrate  [4]. Last decade has seen a tremendous 
growth in the platelet concentrate, with several 
modifications. First generation platelet concentrate Plate 
Rich Plasma (PRP), was popular and remained in this 
field for few years, with natural phenomena to change 
with better understanding of the methods and concepts, 
which gave the way to the development of second 
generation concentrate Platelet Rich Fibrin (PRF) [5, 6]. 
Platelet rich fibrin a modification of platelet concentrate 
is a boon to the periodontal regeneration has seen various 
applications in the field of dentistry. Its simplicity and chair 
side technique attracted naturally many periodontist, oral 
surgeons, dermatologists, orthopaedics professionalsand 
others in the field of medicine and dentistry with open 
hands. Several changes in the methodology in terms of 
speed and material used resulted in the development of 
newer PRF techniques with superior results in terms of 
regeneration. However there is definite variation in the 
final outcome or clinical results when PRF is used for the 
regeneration, which made the researchers to search for the 
factors affecting the same [7, 8]. With the methodological 
factors and materials used, impacting the clinical result, 
there are systemic factors may also contribute to the 
regenerative capability of PRF. 
The first report on the relationship between obesity 
and periodontal disease appeared in 1977, when 
Perlstein et al. observed histopathologic changes in the 
periodontium of hereditary obese Zucker rats (Zucker 
and Zucker, 1962; Perlstein and Bissada, 1977). Using 
ligature induced periodontitis; they found alveolar bone 
resorption to be greater in obese animals compared with 
non-obese rats (Perlstein and Bissada, 1977).
The role of obesity in periodontal disease progression 
is interesting and manifolds  [9]. In humans, systemic 
diseases have always been considered as a risk factor 
for the periodontitis. Obesity is a major independent 
risk factor for hypertension, coronary heart disease, 
osteoarthritis, and, in particular, type 2 diabetes. Among 
Background. The prevalence of obesity has increased substan-
tially in the last few decades. World Health Organization (2020) 
estimated that around 600 million obese adults worldwide were 
obese, and a further increase is expected in the future due to 
increased consumption of high-calorie diets and a sedentary life-
style as per the evidence. 
Aim. To evaluate and compare the level of fibroblast growth 
factor platelet rich fibrin (A-PRF) in obese subject compare to 
healthy weight subject. 
Methods. Blood samples were collected from 23 volunteers, 
15 obese subject (test group) and 8 non-obese (control group) at 
Riyadh Elm University. Considering the smaller sample size of 
our study, the results are to cautiously be interpreted for general-
izability. Studies employing larger sample size are recommended 
to overcome this point. But considering the meticulous study pro-
cedure adhering to the study protocol and set criteria, the study 
pronounces greater internal validity in the sample chosen. The 
medical, dental histories, an interview and clinical examina-
tion was performed to check the eligibility of the participants to 
be involved in this study, Blood sample was collected in 10  ml 
syringe, then being processed using A-PRF centrifugation pro-
tocols. Ten milliliters of whole blood without anticoagulant was 
centrifuged at 1,300 rpm for 14 minutes. 
Results. The level of FGF-2 released from (A-PRF) concentration 
was significantly lower on obese which was measured on 4 different 
times (day 1, day 7, day 14 and day 28), compared to healthy. 
Conclusions. There was decrease in FGF-2 level released from 
(A-PRF) from obese compared to healthy.
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the commonly associated systemic disease diabetes and 
obesity are taking the front row, which has been shown 
to alter the periodontal disease progression and clinical 
outcome in many evidence-based studies. The presence 
of periodontal disease in a diabetic individual is a 
serious health hazard. Based on few studies done, there 
appears to be stronger obesity-periodontitis association 
in women, non-smokers, and younger individuals than 
in the general adult population [1]. 
Obesity has impact on the host cells and molecular 
signaling. PRF, derived from the platelets is a host of 
several growth factors. Growth factors which are the key 
component of initial and later stages of healing process 
are released by several hematopoietic cells, including 
platelets. Growth factors always function in an order 
or in a cycle with the help of other growth factors and 
cytokines. Functioning of many inflammatory cells are 
expected to change the obesity, platelet derived growth 
factors are not immune to this [10]. 
Thus, the present study is expected to explore the PRF 
derived growth factors in obese patients compare to 
non-obese patients, so that the outcome of the study is 
utilized in the regenerative strategy to be employed in 
the obese patients. 
Methods
This was a descriptive, cross sectional study conducted on 
23 subjects, chosen randomly from post-graduate residents 
in dentistry programs at Riyadh Elm University. For 
this, both the medical and dental histories were retrieved 
with an interview and clinical examination, which was 
performed to check the eligibility of the participants. For 
randomization, an electronic mail was sent to all residents 
with a detailed explanation of the procedure asking them 
to respond in case if they are willing to volunteer for the 
study. They were asked to get the Body Mass Index (BMI)
done, and it should be above 30 (obese). After that, the 
positive responses were matched with the study criteria to 
determine the group of the participants that we can take our 
final sample from. Each of matched responses was given a 
number. The final sample was chosen from the sorted group. 
One trained person extracted the blood from all participants 
who was not a part of the research team but involved for the 
expertise skill that performed the centrifugation process for 
all samples. Ethical approval was obtained from research 
committee in Riyadh Elm University with registration 
number FPGRP/43831005/340. 
Preparation of PRF
Blood samples were collected from our volunteers, 
(23 total samples). 15 obese (test group) and 8 normal 
weight (control group). Blood was extracted by 10 ml 
syringe, which was then processed using A-PRF 
centrifugation protocols. Ten milliliters of whole blood 
without anticoagulant was centrifuged at 2,700  rpm 
(708 g) for 12 minutes, the fibrin clots were collected 
after centrifuging from the top of the centrifuge tubes. 
The PRF clots was placed into prepared dishes. For 
each sample, 5 ml of culture medium was added. 
Dulbecco’s modified eagle medium (DMEM) was used 
for this purpose. We used PRF kit and tubes provided 
by PROCESS for PRF Company in France with U.S. 
FDA registration number 3007006186. The centrifuge 
machine used is HERMLE Z 206 A. This machine 
manufactured by HERMLE Labortichnik GmbH, 
Wehingen-Germany.
Protein Quantification with Enzyme-Linked 
Immunosorbent Assay (ELISA)
Principle of the assay
The kit is based on sandwich enzyme-linked immuno-
sorbent assay technology. An antibody specific to FGF2 
is pre-coated on to a 96-well plate. The standards and 
samples are added to the wells, incubated and washed 
with wash buffer. A biotin conjugated antibody specific 
to FGF2 is used for detection. TMB substrate is used 
to visualize HRP activity. TMB is catalyzed by HRP to 
produce a blue color product that changes into yellow 
after adding stop solution. The intensity of yellow is 
proportional to the FGF2 amount bound on the plate and 
then the concentration of FGF2 can be calculated.
To determine the amount of growth factors released from 
PRF at one day, seven days, 14 days, 28 days, samples 
will be kept at 37 C to allow for growth factor release. 
Protein quantification was carried out using ELISA 
machine. At desired time points, FGF-2 was quantified 
using an ELISA kit according to manufacturer protocol. 
Absorbance measured at 450 and 570 nm using a micro 
plate reader and the measurement at 570  nm were 
subtracted from the reading at 450 nm. Also, all samples 
were measured in duplicate.
Statistical analysis 
Data analyses were carried out using Statistical Packages 
for Social Sciences (SPSS) version 21 (SPSS, Chicago, 
IL, USA). Descriptive statistics of FGF2 experiments were 
summarized using mean and standard deviation or median 
(range) whenever appropriate. Normality of test was also 
conducted using Kolmogorov-Smirnov and Shapiro Wilk 
test, p-value  <  0.05 were considered as non-parametric. 
Correlation procedure had also been conducted using 
Pearson correlation. The statistical association of mean 
FGF-2 measured over time among obese and non-obese 
was conducted using independent t-test. Paired t-tests were 
also conducted to measure the mean differences among 
FGF-2 measured over time between each group (obese and 
non-obese). A p-value < 0.05 was considered statistically 
significant and a p-value  <  0.01 was considered highly 
statistically significant. 
Reliability analysis
Interclass Correlation Coefficient (ICC) was applied 
to determine the internal consistency of the study data. 
Based on the results the reliability analysis measured 
among four items (FGF-2 day to day 28) was 0.814 or 
81.4% which indicates a very good internal consistency.
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Results
We collected blood samples from 23  volunteers at 
Riyadh Elm University, 15 of them were classified into 
obese group (test group) and 8 participants were non-
obese (control group). Table I presented the comparison 
between mean FGF-2 measured over time among 
obese and non-obese. It was found that, compared to 
non-obese patients, the level of FGF-2 measurement 
was significantly lower on obese which was measured 
on 4  different occasions (day 1 to day 28) (p  <  0.05; 
95%  CI). The outcome indicated that the lower FGF2 
concentration was associated with obese patients 
whereas higher FGF-2 concentration was associated 
with the normal group (non-obese). 
Figure 1 depicted the distribution of mean FGF-2 which 
was measured in 4 different times (day 1, day 7, day 14 
and day  28) between obese and non-obese. It can be 
shown that FGF-2 measurement among 4 different 
occasions were significantly lower in obese patients 
(p < 0.05).
Figure  2 depicted the trend line of FGF-2 which was 
measured in different times. As revealed, the mean FGF-
2 measurement of non-obese was significantly lower 
at day 1 (mean 2.55) while day 28 was significantly 
higher (mean 2.74). In obese group, mean FGF-2 was 












Obese 1.46 ± 0.52 1.07 ± 0.79 1.53 ± 1.29 0.52 ± 0.66
Non-obese 2.55 ± 0.29 2.59 ± 0.24 2.67 ± 0.43 2.74 ± 0.59
T-test -5.478 -5.209 -2.391 -8.004
P-value § < 0.001 ** < 0.001 ** 0.026 ** < 0.001 **
§ P-value has been calculated using independent t-test; ** Significant at p < 0.05 level. 
Fig. 1. Distribution of Mean FGF2 measured over time comparing obese vs non-obese.
Fig. 2. FGF-2 trend line measured over time between obese and non-obese.
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significantly lower on day 28 (mean 0.52) whereas day 
14 was significantly higher (mean 1.53).
Table  IIA described the Pearson correlation between 
FGF-2 concentration which was measured on different 
occasions such as; day 1, day 7, day 14 and day 28 among 
obese patients. It was determined that, no significant 
correlation was found among day1, day 7, day 17, and 
day 28 in relation to FGF-2 concentration.
In Table IIB where we also conducted Pearson correlation 
in regard to non-obese group. It was determined that 
the correlation between day 7 and day 1 was highly 
statistically significant (r = 0.981, p < 0.001).
Paired t-test was conducted at Table  IIIA to assess the 
mean differences of FGF-2 which was measured over time 
among obese group. It can be seen that the paired t-test 
between day 1 and day 28 was statistically significant 
(p = 0.001). The difference was also statistically significant 
between day 7 and day 28 (p = 0.048) while the paired 
t-test between day 14 and day 28 was also statistically 
significant (p = 0.004).
For the normal group (Tab.  IIIB), the paired t-test 
among FGF-2 measured over time were not statistically 
significant in different occasions.
Discussion 
The periodontal regeneration has become the common 
and most frequently used surgical periodontal therapy in 
periodontics. What has been proved positive technique 
or material for regeneration of lost periodontal structure 
is either improved in their concept or may not be used 
as frequently as before. Though there are many changes 
and advances in the adapted regenerative methods, the 
understanding of the concept of periodontal wound 
healing, cells required for the regeneration and other 
factors behind this therapeutic model are constantly 
Tab. IIA. Correlation (Pearson – R) between FGF-2 measured over-
time among obese group (n = 15).
FGF-2 Day 1 Day 7 Day 14 Day 28
Day 1 1
Day 7 0.282 1
Day 14 -0.122 0.112 1
Day 28 0.030 0.101 0.455 1
Tab. IIB. Correlation (Pearson – R) between FGF-2 measured over-
time among non-obese group (n = 8).
FGF-2 Day 1 Day 7 Day 14 Day 28
Day 1 1
Day 7 0.981 ** 1
Day 14 -0.251 -0.301 1
Day 28 -0.302 0.589 0.632 1
** Significant at p < 0.01 level.
Tab. IIIA. Paired t-test between FGF-2 measured overtime among obese group (n = 15).
FGF-2 Mean differences Mean standard error 95% CI of the difference P-value
Pair 1
Day 1 vs day 7 0.387 0.211 -0.066-0.839 0.088
Pair 2
Day 1 vs day 14 -0.074 0.374 -0.876-0.729 0.847
Pair 3
Day 1 vs day 28 0.935 0.212 0.480-1.391 0.001 **
Pair 4
Day 7 vs day 14 -0.461 0.372 -1.258-0.337 0.236
Pair 5
Day 7 vs day 28 0.549 0.253 0.007-1.091 0.048 **
Pair 6
Day 14 vs day 28 1.009 2.976 3.709-1.647 0.004 **
** Significant at p < 0.05 level.
Tab. IIIB. Paired t-test between FGF-2 measured overtime among non-obese group (n = 8).
FGF-2 Mean differences Mean standard error 95% CI of the difference P-value
Pair 1
Day 1 vs day 7 -0.038 0.027 -0.102-0.028 0.216
Pair 2
Day 1 vs day 14 -0.117 0.207 -0.606-0.371 0.588
Pair 3
Day 1 vs day 28 -0.192 0.259 -0.806-0.421 0.483
Pair 4
Day 7 vs day 14 -0.079 0.196 -0.543-0.384 0.696
Pair 5
Day 7 vs day 28 -0.155 0.241 -0.726-0.416 0.541
Pair 6
Day 14 vs day 28 -0.075 0.162 -0.459-0.309 0.657
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being updated and utilized for the clinical periodontal 
regenerative aspects [11]. 
Platelet-rich fibrin (PRF) first described by Choukroun 
et al.  [12] is a new second generation of platelet 
concentrate. PRF provides a scaffold for cell migration 
and growth factors for promoting wound healing, bone 
regeneration, graft stabilization, wound sealing and 
hemostasis. Because the fibrin matrix is better organized, 
it is able to more efficiently direct stem cell migration 
and the healing program [13]. 
The concept of “natural bone regeneration” was proposed 
by Simonpieri et al. [14]. which includes regeneration of 
gingival tissue and bone volume through PRF membrane. 
Yuchao et al. [15]. showed that the use of PRF as the sole 
grafting material seems to be an effective modality of 
regenerative treatment for periodontal bonedefects. 
In the present study we have taken into consideration that, 
obesity may have a role to play on the PRF. As of our 
knowledge and review of literature till today, it is assumed 
that, this is the first study to be conducted to evaluate the 
relation between the obesity and Fibroblast growth factor 
(FGF) in PRF of obese patients. In consideration of the 
effect of obesity on inflammatory cascade and cells, this 
type of study is well justified [16-18].
The traditional BMI classification underestimates 
risk in Asian and South Asian people. A separate 
guideline for this population classifies overweight as 
a BMI between 23 and 24.9 kg/ m2 and obesity as a 
BMI ≥25 kg/m2 [19]. In the present study we have taken 
into consideration universally adapted definition for 
the obese and overweight patients If the BMI is 25.0 
to < 30, it falls within the overweight range and If the 
BMI is 30.0 or higher, it falls within the obese range. 
Adapting the universally acceptable guideline for the 
obese it helps to compare the previous and future studies 
on same platform. Patient for the present study were 
recruited randomly from the outpatient department. 
Random selection of the patient helps in avoiding the 
sample bias which is helpful in the better interpretation 
of the results [20].
The sample size for the present study estimated as a total 
of 23 patients with 15 patients in the test group (obese) 
and 8 patients (healthy) group. Since it is the kind of first 
study to be conducted, for the sample size estimation, 
other studies done with almost similar background was 
chosen and minimal sample size required interpreting 
the acceptable results was taken into consideration. 
Age group chosen for the study was between 25 to 
50 years of age. Range of the age was acceptably wide 
to include as much as possible aged individuals, with 
caution taken to avoid the impact of aging on the growth 
factors. Age range was suitable to interpret the results 
with both the control and rest group were in the same 
age range with equal inclusion of age range. Thus, the 
probable worsening effect of aging in one group or better 
effect of aging in the younger group was avoided [21].
It is to be noted that, the blood sample for the measurement 
of FGF-2 was done on four intervals across a month. 
The assessment of growth factor over this defined period 
and intervals helps to overcome the one-time changes 
seen in FGF-2 level. It also helps to assess the true 
value and to avoid the one-time impact / on that one 
day impact of cellular changes affected by obesity on 
PRF growth factor. There is possibility of changing the 
inflammatory cascade, cytokines level and growth factor 
level depending upon the metabolic changes induced in 
the obesity. This four-time assessment will overcome all 
these barriers [16, 18, 22].
In the obese group of patients in the present study there 
was lower value of FGF-2 was seen over a month. There 
was significantly low level of FGF-2 was observed at 
first week and comparatively higher level observed 
at the end of the study period. The low level of FGF-
2 in obese patients can be explained on the basis of 
impact of obesity on the other inflammatory cells. It is 
to be remembered that, there is always a viscous cycle 
between the inflammatory cell products like cytokine 
and growth factor which balances the formation and 
resorption of the periodontal tissue. When this balance 
is tilted towards inflammatory side, it predominates the 
destruction over the formation. Viceversa is seen when 
the growth factor dominates the cycle with formation 
of tissue is common. Present study results with low 
FGF-2 level in obese patient is justifiable , because 
its well-known that , in obesity adipocytes secret pro- 
inflammatory cytokines such as TNF-α and IL-6  [12] 
which stimulates the hepatic production of acute phase 
proteins such as C-reactive protein ( CRP) and cause 
alteration in hosts immune response. Further it is also 
shown that, serum adiponectin which exert the anti-
inflammatory effect are reduced and the resisting which 
exerts inflammatory effect are increased [22]. Over and 
above with all these, excessive ROS level and a decrease 
in antioxidant substances also has been reported. All this 
negative alteration in the immune response will shift 
the balance towards destruction and ability of cells like 
platelets to produce lesser growth factors. Thus, one of 
the possible reasons hypothesized for the lower level 
of FGF-2 seen in obese patient PRF is the shift in the 
inflammatory process towards negative balance [18]. 
Though the results can be taken into consideration to 
explain the relation between obese and normal patients 
PRF response, results can be improved in the future 
studies. Obese patient can be further classified according 
to BMI and comparison of the levels of growth factors 
helps us to determine the severity of obesity on level 
of growth factors. This further establishes and explains 
the role of obesity on FGF-2 level. Secondly, though 
the sample size chosen according to available previous 
almost similar observations studies, the sample size 
increased will help to establish the relation far better 
than this initial study. In the present study the gender 
demarcation was not done. Such gender differences if at 
all any seen if reported in terms of growth factor release 
will help to achieve better treatment strategy in obese 
male and obese female patient separately [23]. 
When obese patient PRF related growth factor compared 
to the non-obese or healthy patients it is observed that, 
there is study increase in FGF-2 in the stipulated study 
period. Absence of inflammatory triggers, positive cycle 
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of productivity is expected to release a better growth 
factor release in healthy non obese patients. Repair or 
regeneration overrides the destructive inflammatory 
process and balances the equation with the normal 
production of growth factor required for the normal 
turnover of a cell and tissue [24, 25]. 
Panahi et al.  [26], conducted a cross-sectional study in 
patients with type 2 diabetes. Of the evaluated 141 subjects, 
49 (34.8%) were categorized as having well-controlled 
diabetes, 66 (46.8%) had poorly controlled diabetes, and 
there were 26 subjects in the normal control group. Serum 
FGF21 concentrations were determined in all subjects 
using ELISA. Serum FGF21 level in the poorly controlled 
diabetic group was significantly higher than that in the 
well-controlled diabetic and the healthy control groups 
(p = 0.02) but there was no significant difference between 
the well-controlled and healthy groups. There was no 
significant association between serum FGF21 levels with 
lipid levels, presence of diabetic complications and BMI 
(p > 0.05).
In another study by Mashili et al. [27], levels of circulating 
FGF-21 in 207 overweight and obese Tanzanian males with 
or without type 2 diabetes mellitus (T2DM) were measured. 
They found higher levels of FGF-21 in people with T2DM 
compared to those without the disease. Based on statistical 
models, measures of adiposity explained up to 59% of the 
variability in FGF-21 levels in the circulation.
Conclusions 
Within the limitation of the study the following 
conclusion can be drawn:
• FGF-2 measurement is lower in obese patients.
• It was registered a FGF-2 level increase in normal 
healthy or non-obese patients.
• When FGF-2 levels are compared between the inter-
vals of one week, the FGF-2 level showed significant 
difference in obese patients.
• Study finding may be utilized in the treatment of 
periodontal regeneration in obese patients. 
• The combination of PRF with regenerative therapy 
has been shown to be most promising for periodontal 
repair of boneand furcation defects, as well as soft 
tissue root coverage of gingival recession. However, 
the effect of PRF on pure bone regeneration remains 
questionable as many clinicians are unfamiliar with 
its use and thus requires more validating studies.
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